Literature DB >> 24418295

Diagnostic criteria of autoimmune hepatitis.

Rodrigo Liberal1, Charlotte R Grant2, Maria Serena Longhi2, Giorgina Mieli-Vergani2, Diego Vergani3.   

Abstract

Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disorder characterised by female preponderance, elevated transaminase and immunoglobulin G levels, seropositivity for autoantibodies and interface hepatitis. Presentation is highly variable, therefore AIH should be considered during the diagnostic workup of any increase in liver enzyme levels. A set of inclusion and exclusion criteria for the diagnosis of AIH have been established by the International Autoimmune Hepatitis Group (IAIHG). There are two main types of AIH: type 1, positive for anti-nuclear (ANA) and/or anti-smooth muscle antibodies (SMAs) and type 2, defined by the presence of anti-liver kidney microsomal antibody type 1 (LKM-1) and/or anti-liver cytosol type 1 (LC-1) autoantibodies. The central role of autoantibodies in the diagnosis of AIH has led the IAIHG to produce a consensus statement detailing appropriate and effective methods for their detection. Autoantibodies should be tested by indirect immunofluorescence at an initial dilution of 1/40 in adults and 1/10 in children on a freshly prepared rodent substrate that includes kidney, liver and stomach sections to allow for the simultaneous detection of all reactivities relevant to AIH. Anti-LKM-1 is often confused with anti-mitochondrial antibody (AMA) if rodent kidney is used as the sole immunofluorescence substrate. The identification of the molecular targets of anti-LKM-1 and AMA has led to the establishment of immuno-assays based on the use of the recombinant or purified autoantigens. Perinuclear anti-nuclear neutrophil antibody (p-ANNA) is an additional marker of AIH-1; anti soluble liver antigen (SLA) antibodies are specific for autoimmune liver disease, can be present in AIH-1 and AIH-2 and are associated with a more severe clinical course. Anti-SLA are detectable by ELISA or radio-immuno-assays, but not by immunofluorescence. AIH is exquisitely responsive to immunosuppressive treatment, which should be instituted promptly to prevent rapid deterioration and promote remission and long-term survival.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24418295     DOI: 10.1016/j.autrev.2013.11.009

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  31 in total

Review 1.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

Review 2.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 3.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

4.  Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report.

Authors:  Hiroshi Ohkawara; Miki Furukawa; Kazuhiko Ikeda; Akiko Shichishima-Nakamura; Masahiko Fukatsu; Takahiro Sano; Koki Ueda; Satoshi Kimura; Risa Kanai; Yuka Oka; Fumi Murakami; Osamu Suzuki; Yuko Hashimoto; Kazuei Ogawa; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2017-06-05       Impact factor: 2.490

5.  How should a district general hospital immunology service screen for anti-nuclear antibodies? An 'in-the-field' audit.

Authors:  R Hira-Kazal; P Shea-Simonds; J L Peacock; J Maher
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

6.  Severe transaminitis in a paediatric patient with systemic lupus erythaematosus and a discussion of the literature.

Authors:  Garima Sarda; Rohini Harvey
Journal:  BMJ Case Rep       Date:  2016-04-18

7.  Autoantibody Profiling in a Cohort of Pediatric and Adult Patients With Autoimmune Hepatitis.

Authors:  Danilo Villalta; Elia Girolami; Maria Grazia Alessio; Maria Concetta Sorrentino; Marilina Tampoia; Ignazio Brusca; Massimo Daves; Brunetta Porcelli; Giuseppina Barberio; Mariaelisabetta Conte; Lisa Pantarotto; Nicola Bizzaro
Journal:  J Clin Lab Anal       Date:  2014-09-19       Impact factor: 2.352

8.  Human leucocyte antigens and pediatric autoimmune liver disease: diagnosis and prognosis.

Authors:  Norman Junge; Miriam Tiedau; Murielle Verboom; Michael Hallensleben; Rainer Blasczyk; Jerome Schlue; Imeke Goldschmidt; Eva-Doreen Pfister; Ulrich Baumann
Journal:  Eur J Pediatr       Date:  2015-11-14       Impact factor: 3.183

Review 9.  Transcriptomic Segregation of Human Autoantigens Useful for the Diagnosis of Autoimmune Diseases.

Authors:  Peter D Burbelo; Michael J Iadarola; Ilias Alevizos; Matthew R Sapio
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

Review 10.  PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma.

Authors:  Colleen S Curran; Elad Sharon
Journal:  Semin Oncol       Date:  2018-01-06       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.